a50620601.htm
UNITED STATES
 
SECURITIES AND EXCHANGE COMMISSION
 
Washington, D.C.  20549
 
 

FORM 8-K
 
 
 
CURRENT REPORT
 
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
 
Date of report (Date of earliest event reported): April 30, 2013

 

 
PFIZER INC.
(Exact name of registrant as specified in its charter)

Delaware
1-3619
13-5315170
(State or other
(Commission File
(I.R.S. Employer
jurisdiction of
(Number)
Identification No.)
incorporation)
 
  

 
235 East 42nd Street  10017
New York, New York  (Zip Code) 
(Address of principal executive offices)


Registrant's telephone number, including area code:
(212) 733-2323

Not Applicable
(Former Name or Former Address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 
 

Item 2.02 Results of Operations and Financial Condition

On April 30, 2013, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for the first quarter of 2013. The information contained in the press release is deemed to be “filed” under the Securities Exchange Act of 1934 as Exhibit 99 to this report, and such press release is incorporated herein by reference.


Item 9.01 Financial Statements and Exhibits

(d)  Exhibits
 
Exhibit 99 -   Press Release of Pfizer Inc. dated April 30, 2013, reporting Pfizer's financial results for the first quarter of 2013. Exhibit 99 is deemed to be “filed” under the Securities Exchange Act of 1934 in this Current Report on Form 8-K.
                
 
SIGNATURE
 
Under the requirements of the Securities Exchange Act of 1934, the registrant has caused this report to be signed on its behalf by the authorized undersigned.
 
 
  PFIZER INC. 
     
     
  By:  /s/ Matthew Lepore
   
Matthew Lepore
Vice President and Corporate Secretary 
 
 

Dated: April 30, 2013
 
 
 
 

EXHIBIT INDEX
 
Exhibit No.  Description 
   
99 Press Release of Pfizer Inc. dated April 30, 2013, reporting Pfizer's financial results for the first quarter of 2013.